May 19, 2022
Article
TROP-2 and Nectin-4, surface cell targets of sacituzumab govitecan and enfortumab vedotin, respectively, are highly expressed in variant histology bladder cancer.
April 12, 2022
Article
High genomic loss of heterozygosity may serve as a predictive marker for response to talazoparib in patients with metastatic castration-resistant prostate cancer.
February 18, 2022
Article
“Not only does a deep PSA response identify patients who will have improved survival and progression-free outcomes, but also it is also associated with maintenance of health-related quality of life, improved patient reported physical wellbeing, and a reduced risk of worsening pain and fatigue intensity,” said Eric Jay Small, MD.
February 18, 2022
Article
Patients treated with apalutamide achieved a PSA90 response at a 70.4% rate compared with 62.5% of patients who received enzalutamide at the end of the 12-month follow-up.